News | February 09, 2012

IsoRay Applauds Cleveland Clinic Prostate Study Conclusions on Brachytherapy Superiority

Company's Cesium-131 Positioned As Major Beneficiary

February 9, 2012 — IsoRay Inc., a medical technology company with specialty in seed brachytherapy and medical radioisotope applications, said that the findings of a Cleveland Clinic study add to evidence supporting the efficacy of brachytherapy. The Cleveland Clinic study compared external beam radiation, prostatectomy (the surgical removal of the prostate) and brachytherapy (internal radiation therapy). The study, which examined the treatment outcomes for 137,000 men over a five-year period, found brachytherapy to have the fewest number of toxicities involving genital or urinary organs and the lowest total cost per patient per year. The Cleveland Clinic researchers are the first to examine the quality of life and financial costs of the three most common prostate cancer treatments over a prolonged period after treatment.

IsoRay CEO Dwight Babcock said the findings were "confirmation of what we have known at IsoRay for some time. Brachytherapy low dose internal radiation is the most effective and cost efficient therapy available, along with having the fewest complications. Importantly, we are the only brachytherapy company with an isotope (Cesium-131) that has enough energy and the short half life needed to combat fast growing, aggressive cancers located anywhere in the body. Going forward, it is my hope that this study will serve to shift the focus back to brachytherapy as physicians receive further confirmation of its superiority."

IsoRay is the exclusive manufacturer of Cesium-131. This brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years. Cs-131 seeds deliver radiation quickly and aggressively compared to other types of internal, low-dose rate radiation. Brachytherapy with Cs-131 is minimally invasive; provides higher energy, more rapid delivery of a uniform dose of radiation; and has a shorter half life (9.7 days) than other radioactive isotopes used in internal radiation therapy. The groundbreaking treatment impacts longevity and cure rates and can be performed outside a hospital setting, resulting in a faster return of a patient to normal activity.

Babcock says he strongly believes the expected upcoming release of IsoRay's 5 year data on the use of Cesium-131 to treat prostate cancer will provide further compelling evidence for doctors and the patients they treat regarding the choice of Cesium-131.

For more information: www.isoray.com

Related Content

MRI Reveals Striking Brain Differences in People with Genetic Autism

Example images for a control participant , a deletion carrier, and a duplication carrier. In the sagittal image of the deletion carrier, the thick corpus callosum, dens and craniocervical abnormality, and cerebellar ectopia are shown. For the duplication carrier, the sagittal image shows the thin corpus callosum and the axial image shows the increased ventricle size and decreased white matter volume. Image courtesy of the Radiological Society of North America (RSNA).

News | Neuro Imaging | August 09, 2017
August 9, 2017 — In the first major study of its kind, researchers using magnetic...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
brain with chronic traumatic injury
News | Magnetic Resonance Imaging (MRI) | August 02, 2017
Fighters are exposed to repeated mild traumatic brain injury (mTBI), which has been associated with neurodegenerative...
NIH-funded scientists have discovered that Parkinson’s disease increases the amount of “free” water in a particular brain area

NIH-funded scientists have discovered that Parkinson’s disease increases the amount of “free” water in a particular brain area. Image courtesy of David Vaillancourt, Ph.D., University of Florida.

News | Neuro Imaging | July 31, 2017
Scientists at the University of Florida have discovered a new method of observing the brain changes caused by Parkinson...
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
"Residual Echo" of Ancient Humans May Hold Clues to Mental Disorders

MRI data shows (left) areas of the skull preferentially affected by the amount of Neanderthal-derived DNA and (right) areas of the brain’s visual system in which Neanderthal gene variants influenced cortex folding (red) and gray matter volume (yellow). Image courtesy of Michael Gregory, M.D., NIMH Section on Integrative Neuroimaging

News | Neuro Imaging | July 26, 2017
Researchers from the National Institute of Mental Health (NIMH) have produced the first direct evidence that parts of...
New York Hospital Finds Significant Cost Savings With Toshiba’s Aquilion One CT
News | Computed Tomography (CT) | July 25, 2017
In five years, Kaleida Health’s Stroke Care Center (SCC) at the Gates Vascular Institute in Buffalo, N.Y., has realized...
Radiotherapy Prior to Surgery Reduces Secondary Tumor Risk in Early-Stage Breast Cancer Patients
News | Radiation Therapy | July 24, 2017
Moffitt Cancer Center researchers launched a first-of-its-kind study comparing the long-term benefits of radiation...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
Overlay Init